With Clinical Validation Study Complete, Sequenom Moves Ahead with 2012 Launch of T21 Test

In the company's first-quarter earnings call, Sequenom CEO Harry Hixson said he believes that other companies developing similar sequencing-based trisomy 21 tests are infringing Sequenom's intellectual property.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.